Vol. 2 No. 4 (2022)
Reimbursement Reviews

Trientine Hydrochloride (Waymade-Trientine)

Published April 5, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses trientine hydrochloride (Waymade-Trientine), 250 mg capsules, oral.
  • Indication: For the treatment of patients with Wilson disease who are intolerant to penicillamine.